Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up results from JCOG1704
Gastric Cancer · 2026
DOI: 10.1007/s10120-026-01766-3 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Gastric Cancer, 2026. Verfasst von Yukinori Kurokawa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan. yku…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The University of Osaka.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Prognosis of marginally resectable gastric cancer with extensive lymph node metastasis (ELM) remains poor, even after R0 resection. JCOG0405 established preoperative cisplatin plus S-1 as a provisional standard of care in Japanese guidelines, based on a favorable 3-year overall survival (OS) of 58.8%. We report the 3-year survival outcomes of JCOG1704, a phase II trial evaluating preoperative docetaxel, oxaliplatin, and S-1 (DOS) for marginally resectable gastric cancer with ELM, following promising short-term outcomes.
Methods
Patients with histologically confirmed HER2-negative gastric adenocarcinoma and bulky nodal (BN) involvement and/or para-aortic node (PAN) metastasis were eligible. Patients received three cycles of DOS (docetaxel 40 mg/m 2 , day 1; oxaliplatin 100 mg/m 2 , day 1; S-1 80–120 mg/m 2 , days 1–14) every 3 weeks, followed by gastrectomy with D2 plus PAN dissection and postoperative S-1 for 1 year.
Results
Between December 2018 and March 2022, 47 patients (BN only, 20; PAN only, 17; both, 10) were enrolled. At the data cutoff date (May 2025), the 3-year OS and progression-free survival (PFS) were 86.7% (95% CI 72.7–93.8%) and 75.6% (95% CI 60.2–85.6%), respectively, among 46 eligible patients. Among 42 patients who underwent R0 resection, the 3-year relapse-free survival (RFS) was 78.6% (95% CI 62.9–88.2%). In subgroup analyses, the 3-year OS/PFS/RFS were 85.0%/75.0%/77.8% in BN only, 93.8%/81.3%/86.7% in PAN only, and 77.8%/66.7%/66.7% in both.
Conclusions
Preoperative DOS for gastric cancer with ELM yielded unprecedentedly favorable 3-year survival outcomes and was considered a provisional standard of care without a phase III trial within our JCOG community.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan. ykurokawa@gesurg.med.osaka-u.ac.jp.
- Department of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, 2-2-E2, Yamadaoka, Suita, Osaka, 565-0871, Japan.
- Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
- Department of Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan.
- Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
- Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.
Förderung
- The University of Osaka
Zitieren
APA
Kurokawa, Y., Doki, Y., Mizusawa, J., Kawabata, K., Nomura, T., Tsuji, K., Lee, S. W., Cho, H., Hihara, J., Hiki, N., Nunobe, S., Boku, N., Terashima, M., & Yoshikawa, T. (2026). Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up results from JCOG1704. Gastric Cancer. https://doi.org/10.1007/s10120-026-01766-3
Vancouver
Kurokawa Y, Doki Y, Mizusawa J, Kawabata K, Nomura T, Tsuji K, et al. Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up results from JCOG1704. Gastric Cancer. 2026. doi:10.1007/s10120-026-01766-3
BibTeX
@article{Kurokawa2026,
author = {Kurokawa, Yukinori and Doki, Yuichiro and Mizusawa, Junki and Kawabata, Kota and Nomura, Takashi and Tsuji, Kunihiro and Lee, Sang-Woong and Cho, Haruhiko and Hihara, Jun and Hiki, Naoki and Nunobe, Souya and Boku, Narikazu and Terashima, Masanori and Yoshikawa, Takaki},
title = {Preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis: 3-year follow-up results from JCOG1704},
journal = {Gastric Cancer},
year = {2026},
doi = {10.1007/s10120-026-01766-3}
}
EUVIMED